Stocks Health care EVMN
NYSE · Health careEvommune, Inc. (EVMN)
Evommune, Inc. brought in $10M of revenue over the twelve months to June 30, 2026. It posted a net loss of $94.7M. In fiscal 2025 capital spending exceeded operating cash flow by $76.7M. At June 30, 2026 it held $60M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
Key facts about Evommune, Inc.
- Net worth
- Evommune, Inc. has a market value (market cap) of $277.6M at the latest share price, and shareholders' equity of $277.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $13M (+85.7% year on year), with a net loss of $68.9M. Over the 12 months to June 30, 2026: revenue $10M, net loss $94.7M.
- Cash flow
- In fiscal 2025 operations used $76.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 6, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Evommune, Inc.'s next report was expected around October 29, 2026 and is not on file with the SEC yet.
What Evommune, Inc. does
Evommune, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker EVMN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $13M | -$68.9M | -$11.22 | -$76.7M |
| 2025 | $7M | -$66.8M | -$45.29 | -$58.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where EVMN ranks in Health care
Latest SEC filings
What Evommune, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026
- November 4, 2026
- October 1, 2026
- September 23, 2026
- September 15, 2026
- September 9, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026
- August 6, 2026
Insider trades
What the people running Evommune, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 1 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 30, 2026 | Pena Luis C.President & CEO, Director | Received as pay | 1,115 | $7.8K |
| July 8, 2026 | Carver KyleChief Financial Officer | Bought | 1,000 | $13.3K |
| July 7, 2026 | Kirsch Arthur SDirector | Boughtindirect | 10,000 | $133K |
| June 22, 2026 | Pena Luis C.President & CEO, Director | Soldpre-planned (10b5-1) | 7,438 | $168.9K |
| June 22, 2026 | Drew Janice SuzannChief of Dev. Operations | Exercised options | 3,839 | $14.7K |
| June 22, 2026 | Drew Janice SuzannChief of Dev. Operations | Exercised options | 16,161 | $48.3K |
| June 22, 2026 | Drew Janice SuzannChief of Dev. Operations | Soldpre-planned (10b5-1) | 20,000 | $452.6K |
| June 22, 2026 | Patel Jeegar PravinkumarChief Scientific Officer | Exercised options | 1,488 | $5.7K |
Who owns EVMN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| LSP 7 Cooperatieve U.A.13D, may seek influence with 1 related filers | 14.7% | February 19, 2026 |
| Nan Fung Group Holdings Limited13G, passive with 12 related filers | 10.9% | February 13, 2026 |
| RA Capital Management, L.P.13D, may seek influence with 3 related filers | 9.7% | February 17, 2026 |
| T. Rowe Price Associates, Inc.13G, passive | 5.4% | August 14, 2026 |
| Point72 Asset Management, L.P.13G, passive with 2 related filers | 5.3% | July 16, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 105 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| EQT Fund Management S.a r.l. | 5,288,313 | +358,680 |
| RA Capital Management, L.P. | 3,494,638 | 0 |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,926,943 | 0 |
| Jpmorgan Chase & Co | 1,553,132 | +93,712 |
| Rtw Investments, LP | 1,502,235 | 0 |
| Nan Fung Group Holdings Ltd | 1,441,032 | 0 |
| Point72 Asset Management, L.P. | 1,435,049 | +1,398,472 |
| Andera Partners | 1,391,990 | -505,372 |
| Eventide Asset Management, LLC | 1,209,129 | 0 |
| Vestal Point Capital, LP | 1,000,000 | new |
| Jupiter Topco LLC | 896,700 | new |
| BlackRock, Inc. | 886,538 | +212,967 |
| Vanguard Capital Management LLC | 881,895 | +426,844 |
| Baker Bros. Advisors LP | 847,390 | 0 |
| Defilade Capital Management, L.P. | 793,145 | +114,556 |
| American Century Companies Inc | 755,018 | +262,080 |
| Alyeska Investment Group, L.P. | 704,425 | -21,937 |
| Balyasny Asset Management L.P. | 457,015 | new |
| Velan Capital Investment Management LP | 451,255 | +5,000 |
| UBS Group AG | 413,553 | +115,178 |
Insiders
13 insiders reported holding 19,683,622 shares in total, about $150.6M at the last price.
| Holder | Shares |
|---|---|
| LSP 7 Cooperative UADirector, 10% owner | 10,217,9465,288,313 held indirectly |
| Verduyn-van Weegen Felice IsabelDirector, 10% owner | 5,288,3135,288,313 held indirectly |
| Ra Capital Management, L.P.Director | 2,710,2932,710,293 held indirectly |
| Pena Luis C.President & CEO, Director | 631,573 |
| Pivotal bioVenture Partners Fund I, L.P.Director, 10% owner | 294,502294,502 held indirectly |
| Bauer EugeneChief Medical Officer, Director | 270,818 |
| Drew Janice SuzannChief of Dev. Operations | 67,794 |
| Moss Gregory S.Chief Business & Legal Officer | 64,0103,175 held indirectly |
| Carver KyleChief Financial Officer | 60,335 |
| Patel Jeegar PravinkumarChief Scientific Officer | 46,403 |
Questions about EVMN
What does Evommune, Inc. do?
Evommune, Inc. is a company in the Health care sector, listed on NYSE as EVMN. Its shares trade on NYSE under the ticker EVMN.
What is Evommune, Inc.'s net worth?
Evommune, Inc. has a market value (market cap) of $277.6M at the latest share price, and shareholders' equity of $277.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Evommune, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $94.7M on revenue of $10M.
How much revenue does Evommune, Inc. make?
Over the twelve months to June 30, 2026 Evommune, Inc. reported revenue of $10M.
When did Evommune, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from November 5, 2026.
When is Evommune, Inc.'s next earnings report?
Evommune, Inc.'s next report was expected around October 29, 2026 and is not on file with the SEC yet.
Similar companies
Compare EVMN with
Follow EVMN
Get an email when Evommune, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Evommune, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.